Literature DB >> 17320443

Obese adults with primary growth hormone resistance (Laron Syndrome) have normal endothelial function.

M Shechter1, S Ginsberg, M Scheinowitz, M S Feinberg, Z Laron.   

Abstract

OBJECTIVE: Classic Laron Syndrome (LS) is a recessive disease of insulin-like growth factor I (IGF-I) deficiency and primary growth hormone insensitivity, clinically characterized by dwarfism and marked obesity. The aim of the current study was to investigate the impact of long-term IGF-I deficiency on flow-mediated dilation (FMD) in 11 non-IGF-I-treated LS adults with long-term IGF-I deficiency who on stress echocardiography were found to have reduced cardiac dimensions and output, but normal left ventricular (LV) ejection fraction at rest and LV contractile reserve following stress.
DESIGN: Following an overnight fast we assessed percent improvement in endothelium-dependent FMD (%FMD) and endothelium-independent nitroglycerin (%NTG)-mediated vasodilation non-invasively in the brachial artery, using high resolution ultrasound in 11 non-treated adult patients with LS without known coronary artery disease, and compared them to 11 age- and sex-matched healthy controls. All subjects underwent symptom-limited exercise testing (Bruce protocol).
RESULTS: LS patients had a significantly higher body mass index (29+/-6 vs. 25+/-2 kg/m(2), p=0.04), lower low-density lipoprotein cholesterol (142+/-28 vs. 176+/-12 mg/dl, p=0.03) and a smaller mean brachial artery diameter (4.63+/-0.72 vs. 5.70+/-1.06 mm, p=0.01) compared to controls. However, brachial artery %FMD and %NTG were not significantly different between the LS patients and controls (13.1+/-6.2% vs. 15.4+/-5.2%, p=0.28 and 22.3+/-6.0% vs. 18.9+/-6.2%, p=0.30; respectively). Cardiac performance, assessed by exercise duration time and metabolic equivalents (METs), was significantly greater in control subjects than in LS patients (10.3+/-2.0 vs. 6.0+/-1.4 min, p<0.01 and 10.2+/-2.0 vs. 7.2+/-1.4 METs, p<0.01; respectively).
CONCLUSIONS: FMD was found to be within normal limits in non-IGF-I-treated adult patients with LS, despite congenital absence of IGF-I and obesity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320443     DOI: 10.1016/j.ghir.2007.01.009

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  13 in total

Review 1.  Healthspan and longevity can be extended by suppression of growth hormone signaling.

Authors:  Andrzej Bartke
Journal:  Mamm Genome       Date:  2016-02-24       Impact factor: 2.957

2.  Both flow-mediated vasodilation procedures and acute exercise improve endothelial function in obese young men.

Authors:  Weili Zhu; Jing Zeng; Jun Yin; Fan Zhang; Hao Wu; Shoufu Yan; Shouheng Wang
Journal:  Eur J Appl Physiol       Date:  2010-03       Impact factor: 3.078

Review 3.  Healthy aging: is smaller better? - a mini-review.

Authors:  Andrzej Bartke
Journal:  Gerontology       Date:  2012-01-18       Impact factor: 5.140

4.  Connecting serum IGF-1, body size, and age in the domestic dog.

Authors:  Kimberly A Greer; Larry M Hughes; Michal M Masternak
Journal:  Age (Dordr)       Date:  2010-09-24

Review 5.  Pleiotropic effects of growth hormone signaling in aging.

Authors:  Andrzej Bartke
Journal:  Trends Endocrinol Metab       Date:  2011-08-17       Impact factor: 12.015

Review 6.  The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances.

Authors:  Zoltan Ungvari; Anna Csiszar
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-26       Impact factor: 6.053

Review 7.  Links between growth hormone and aging.

Authors:  Andrzej Bartke; Reyhan Westbrook; Liou Sun; Mariusz Ratajczak
Journal:  Endokrynol Pol       Date:  2013       Impact factor: 1.582

8.  Young little mice express a premature cardiovascular aging phenotype.

Authors:  Anilkumar K Reddy; Craig J Hartley; Thuy T Pham; Gretchen Darlington; Mark L Entman; George E Taffet
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-05-16       Impact factor: 6.053

9.  The somatotropic axis and aging: mechanisms and persistent questions about practical implications.

Authors:  Andrzej Bartke
Journal:  Exp Gerontol       Date:  2009-04-14       Impact factor: 4.032

Review 10.  Growth hormone and aging: a challenging controversy.

Authors:  Andrzej Bartke
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.